DGAP-News
366
0 Kommentare
Vita 34 AG: Increase in Profitability in Q1 Confirms Positive Growth Outlook 2014 - Seite 3
366 
0 Kommentareincrease in revenues and an increase in EBITDA to approx. EUR 3.3 million.
The complete interim report for the first three months of 2014 is available
for download as of today on the website at www.vita34group.de in the
"Investor Relations" section.
Company Profile
Vita 34 was founded in 1997 as the first private umbilical cord blood bank
in Europe and, as a complete provider, offers collection logistics,
preparation and storage of umbilical cord blood and tissue. The basis for
its successful work is an outstanding position in the technological segment
of cryo-preservation. Here, cells and tissues are preserved alive at
temperatures around minus 190 degrees Celsius, and can be used if needed in
the context of medical treatment. Parents of more than104,000 children are
already taking advantage of this offering and have provided for their
children with a stem cell deposit.
End of Corporate News
---------------------------------------------------------------------
24.04.2014 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Vita 34 AG
Deutscher Platz 5a
04103 Leipzig
Germany
Phone: +49(0341)48792-40
Fax: +49(0341)48792-39
E-mail: ir@vita34.de
Internet: www.vita34.de
ISIN: DE000A0BL849
WKN: A0BL84
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, München,
Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
264364 24.04.2014
in Europe and, as a complete provider, offers collection logistics,
preparation and storage of umbilical cord blood and tissue. The basis for
its successful work is an outstanding position in the technological segment
of cryo-preservation. Here, cells and tissues are preserved alive at
temperatures around minus 190 degrees Celsius, and can be used if needed in
the context of medical treatment. Parents of more than104,000 children are
already taking advantage of this offering and have provided for their
children with a stem cell deposit.
End of Corporate News
---------------------------------------------------------------------
24.04.2014 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Vita 34 AG
Deutscher Platz 5a
04103 Leipzig
Germany
Phone: +49(0341)48792-40
Fax: +49(0341)48792-39
E-mail: ir@vita34.de
Internet: www.vita34.de
ISIN: DE000A0BL849
WKN: A0BL84
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, München,
Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
264364 24.04.2014
Diskutieren Sie über die enthaltenen Werte
Aktuelle Themen
Weitere Artikel des Autors
Verfasst von EQS Group AG
URL kopieren
Per E-Mail teilen
Artikel drucken1 im Artikel enthaltener WertIm Artikel enthaltene Werte
Artikel zu den Werten
Auch bei Lesern beliebt
